Liver diseases, including NAFLD, may lead to enhanced catabolism and/or the inactivation of PON1 molecules [24], which is a potential explanation for the low PON1 activity, as observed in the present meta-analysis. Here, PON1 is linked to metabolic dysfunction-associated steatotic liver disease.